CXCR4 and metastatic prostate carcinoma: There have been successful clinical applications of chemokine therapies, such as the CXCR4 antagonist AMD3100 for treating relapsed or refractory acute myeloid leukemia (AML) and the CCL2 inhibitor CNTO 888 for metastatic prostate cancer (135).